Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Buy

Debt to Equity Rating

Strong Sell

Price to Earnings Rating

Strong Sell

Analyst Rating

Sell

Simple Moving Average

Strong Buy

Exponential Moving Average

Strong Buy

Relative Strength Index

Strong Buy

Standard Deviation

Strong Buy

Williams %R

Strong Buy

Average Directional Index

Neutral

Insider Trading

Neutral

Wall Street Data Solutions Rating

Buy

A

Guardant Health, Inc. Common Stock (GH)

Services-medical Laboratories

https://www.guardanthealth.com

Guardant Health, Inc, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant OMNI, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease, or MRD, test. In 2022, the company launched Shield, a liquid biopsy for colorectal cancer, or CRC, screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.

3100 HANOVER STREET
PALO ALTO, CA

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

10/04/2018

Market Cap

3,495,055,020

Shares Outstanding

121,380,000

Weighted SO

121,379,686

Total Employees

N/A

Upcoming Earnings

08/01/2024

Similar Tickers

NVTA --.--%

ILMN --.--%

TWST --.--%

NTRA --.--%

CDNA --.--%

MYGN --.--%

CSTL --.--%

PSNL --.--%

A --.--%

Beta

1.1290

Last Div

0.0000

Range

15.81-41.06

Chg

-0.1300

Avg Vol

2199661

Mkt Cap

3495055020

Exch

NASDAQ

Country

US

Phone

855 698 8887

DCF Diff

21.5581

DCF

53.0331

Div Yield

0.0000

P/S

5.4287

EV Multiple

-7.5215

P/FV

-2156.6765

Div Yield %

0.0000

P/E

-7.0885

PEG

-0.2582

Payout

-0.0432

Current Ratio

6.3997

Quick Ratio

6.0674

Cash Ratio

5.1359

DSO

56.9880

DIO

214.0982

Op Cycle

271.0862

DPO

135.6716

CCC

135.4146

Gross Margin

0.8226

Op Margin

-0.7943

Pretax Margin

-0.7615

Net Margin

-0.7623

Eff Tax Rate

-0.0010

ROA

-0.3049

ROE

-4.3271

ROCE

-0.3632

NI/EBT

1.0010

EBT/EBIT

0.9588

EBIT/Rev

-0.7943

Debt Ratio

0.7263

D/E

-724.6863

LT Debt/Cap

1.0014

Total Debt/Cap

1.0014

Int Coverage

132.2356

CF/Debt

-0.2402

Equity Multi

-997.7309

Rec Turnover

6.4049

Pay Turnover

2.6903

Inv Turnover

1.7048

FA Turnover

2.3123

Asset Turnover

0.4000

OCF/Share

-2.2933

FCF/Share

-2.4440

Cash/Share

8.4546

OCF/Sales

-0.4362

FCF/OCF

1.0657

CF Coverage

-0.2402

ST Coverage

-10.1509

CapEx Coverage

-15.2115

Div&CapEx Cov

-7.0814

P/BV

-2156.6765

P/B

-2156.6765

P/S

5.4287

P/E

-7.0885

P/FCF

-11.6788

P/OCF

-12.3884

P/CF

-12.3884

PEG

-0.2582

P/S

5.4287

EV Multiple

-7.5215

P/FV

-2156.6765

DPS

0.0000

Latest Headlines (EST)

GlobeNewswire Inc. Jun 26, 02:00 Raphe mPhibr Secures $100M to Expand Aircraft Design and Manufacturing in India The Motley Fool May 16, 23:30 Guardant Health: A Promising Player in the Liquid Biopsy Market GlobeNewswire Inc. Feb 26, 01:30 Liquid Biopsy Market Worth US$11.3 billion at a robust CAGR of 11.9% | MarketsandMarkets™. GlobeNewswire Inc. Feb 05, 01:52 GH Research Announces Pricing of $150 Million Public Offering GlobeNewswire Inc. Nov 30, 05:41 Notice of Delisting and Re-Compliance of Nasdaq Listing Rule GlobeNewswire Inc. Nov 27, 00:30 Personalized Medicines Market to Surpass Valuation of USD 1352.81 Billion by 2031 | SkyQuest Technology The Motley Fool Nov 03, 19:30 Billionaire Investor Ken Griffin Foresees New Highs for the Market After the Presidential Election. Here's Why. The Motley Fool Oct 30, 22:52 Why Guardant Health Stock Was the Picture of Health Today GlobeNewswire Inc. Sep 13, 00:30 Liquid Biopsy Market to Reach $ 32.54 Billion, Globally, by 2033 at 11.61% CAGR: The Brainy Insights Investing.com Jul 24, 04:22 Australian Shares Slip After US Market Decline By Kalkine Media - Investing.com Australia Benzinga Jul 19, 02:12 Cathie Wood-Led Ark Invest Sells $8M In Tesla Shares Despite Bullish Autonomy Forecast - Benzinga GlobeNewswire Inc. May 23, 23:30 Tornado Global Hydrovacs Reports First Quarter 2024 Results GlobeNewswire Inc. Jan 18, 16:30 GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression GlobeNewswire Inc. Jan 17, 16:56 Textainer Announces Date Of Special Meeting And Publication Of Its Proxy Statement To Approve Acquisition By Stonepeak Zacks Investment Research Jan 16, 20:57 3 Stocks to Buy After Massive Earnings Beats Zacks Investment Research Jan 16, 20:57 3 Stocks to Buy After Massive Earnings Beats Zacks Investment Research Jan 16, 20:57 3 Stocks to Buy After Massive Earnings Beats Zacks Investment Research Jan 16, 20:57 3 Stocks to Buy After Massive Earnings Beats Zacks Investment Research Jan 15, 12:20 Surging Earnings Estimates Signal Upside for SMART Global Holdings, Inc. (SGH) Stock Zacks Investment Research Jan 15, 12:20 Surging Earnings Estimates Signal Upside for SMART Global Holdings, Inc. (SGH) Stock

Revenue Product Segmentation